+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) - Pipeline Insight, 2020

  • ID: 4989035
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 106 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • 4SC AG
  • Hoffmann-La Roche
  • Innate Pharma
  • Mallinckrodt
  • Seattle Genetics, Inc.
  • MORE
Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Overview

Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) market. A detailed picture of the Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) pipeline landscape is provided, which includes the disease overview and Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) treatment guidelines. The assessment part of the report embraces in-depth Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) commercial assessment and clinical assessment of the Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) of pipeline development activities

The report provides insights into:
  • All of the companies that are developing therapies for the treatment of Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) treatment.
  • Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Analytical Perspective

In-depth Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Commercial Assessment Of Products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Clinical Assessment Of Products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) .
Report Highlights
  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) .
  • In the coming years, the Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) treatment market. Several potential therapies for Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Questions
  • What are the current options for Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) treatment?
  • How many companies are developing therapies for the treatment of Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS)?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS)?
  • How many Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS)?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS)?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) therapies?
  • What are the clinical studies going on for Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS)?
  • How many patents are granted and pending for the emerging therapies for the treatment of Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS)?


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4SC AG
  • Hoffmann-La Roche
  • Innate Pharma
  • Mallinckrodt
  • Seattle Genetics, Inc.
  • MORE
1. Report Introduction

2. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS)
2.1. Overview
2.2. History
2.3. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Diagnosis
2.6.1. Diagnostic Guidelines

3. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Current Treatment Patterns
3.1. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Treatment Guidelines

4. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Late Stage Products (Phase-III)

7. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Discontinued Products

13. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Key Companies

15. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Unmet Needs

18. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Future Perspectives

19. Relapsed or Refractory Mycosis Fungoides (MF) AND Sézary Syndrome (SS) Analyst Review

20. Appendix

21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Note: Product cover images may vary from those shown
3 of 3
  • Sorrento Therapeutics, Inc.
  • Hoffmann-La Roche
  • Mallinckrodt
  • Innate Pharma
  • 4SC AG
  • Seattle Genetics, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll